AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Syntara Ltd

0.031

-0.001-3.13%

Volume:2.58M

Turnover:80.19K

Market Cap:50.60M

PE:-4.28

High:0.032

Open:0.032

Low:0.031

Close:0.032

52wk High:0.089

52wk Low:0.023

Shares:1.63B

Float Shares:1.00B

Volume Ratio:6.82

T/O Rate:0.26%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.007

EPS(LYR):-0.005

ROE:-90.51%

ROA:-47.51%

PB:4.77

PE(LYR):-5.75

Loading ...

Overview Company News Filings

Syntara's Pancreatic Cancer Drug Candidate to be Subject of Australian Government-Funded Clinical Study

MT Newswires Live

Syntara Ltd-Company Secretary Appointment/Resignation

THOMSON REUTERS

Syntara Enrolls Final Patient in Drug Candidate Study for Treatment of REM Sleep Behaviour Disorder

MT Newswires Live

Is Syntara (ASX:SNT) In A Good Position To Deliver On Growth Plans?

Simply Wall St.

Syntara Ltd-Chair's Address to Shareholders

THOMSON REUTERS

Syntara's Final Phase 2 Results Underscore Safety, Tolerability, Says Euroz Hartleys, Shares Jump 19%

MT Newswires Live

FDA Feedback Pushes Back Syntara Myelofibrosis Drug Candidate Commercial Launch by Around Two Years, Euroz Hartleys Says

MT Newswires Live

Syntara Says US FDA Provides Guidance for Phase 2 Trial for Myelofibrosis Drug Candidate; Shares Plunge 47%

MT Newswires Live

Syntara Ltd-Quarterly Update Webinar Presentation

THOMSON REUTERS

Syntara Ltd-Appendix 4C Quarterly Webinar

THOMSON REUTERS

Syntara Ltd-Quarterly Shareholder Report

THOMSON REUTERS

Syntara Doses First Patient in Hypertrophic Scar Treatment Drug Study

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/SNT.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SNT.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"SNT.AU\",,,,,undefined,":{"symbol":"SNT.AU","market":"AU","secType":"STK","nameCN":"Syntara Ltd","latestPrice":0.031,"timestamp":1772773920000,"preClose":0.032,"halted":0,"volume":2584438,"delay":0,"changeRate":-0.03125000000000003,"nameEN":"Syntara Ltd","floatShares":1004676595,"shares":1632399195,"eps":-0.007236,"marketStatus":"Market Closed","change":-0.001,"latestTime":"03-06 16:12:00 AEDT","open":0.032,"high":0.032,"low":0.031,"amount":80194,"amplitude":0.03125,"askPrice":0.033,"askSize":15500,"bidPrice":0.031,"bidSize":397575,"shortable":3,"etf":0,"ttmEps":-0.007236,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1773010800000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.032,"openAndCloseTimeList":[[1772751600000,1772773200000]],"volumeRatio":6.8234113189918295,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"SNT.AU\",,,,,undefined,":{"symbol":"SNT.AU","floatShares":1004676595,"roa":"-47.51%","roe":"-90.51%","lyrEps":-0.005389,"volumeRatio":6.8234113189918295,"shares":1632399195,"dividePrice":0,"high":0.032,"amplitude":0.03125,"preClose":0.032,"low":0.031,"week52Low":0.023,"pbRate":"4.77","psRate":"6.75","week52High":0.089,"institutionHeld":0,"latestPrice":0.031,"committee":0.924953,"eps":-0.007236,"divideRate":0,"volume":2584438,"delay":0,"ttmEps":-0.007236,"open":0.032,"prevYearClose":0.035,"prevWeekClose":0.031,"prevMonthClose":0.031,"prevQuarterClose":0.035,"fiveDayClose":0.031,"twentyDayClose":0.035,"sixtyDayClose":0.03},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SNT.AU\",params:#limit:5,,,undefined,":[{"date":"2025-05-01","symbol":"SNT.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1746057600000,"name":null,"time":"","dateTimestamp":1746021600000,"actualEps":null},{"market":"AU","date":"2024-10-29","symbol":"SNT.AU","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1730120400000,"reportTimeType":"pre","actualEps":null},{"date":"2024-04-30","symbol":"SNT.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1714435200000,"name":null,"time":"","dateTimestamp":1714399200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SNT.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SNT.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2605122162","title":"Syntara's Pancreatic Cancer Drug Candidate to be Subject of Australian Government-Funded Clinical Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2605122162","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605122162?lang=en_us&edition=fundamental","pubTime":"2026-01-21 12:07","pubTimestamp":1768968426,"startTime":"0","endTime":"0","summary":"Syntara  said a study to evaluate its advanced pancreatic cancer drug candidate amsulostat, or SNT-5505, in combination with standard-of-care chemotherapy will be one of the two multi-center Australian clinical studies conducted after the Garvan Institute of Medical Research in Sydney secured a AU$3 million grant under the Australian Government's Medical Research Future Fund, according to a Wednesday Australian bourse filing.The study will assess safety and clinical activity, as well as conduct deep molecular and genetic profiling of tumor and blood samples collected before and during treatment, the filing said.Both studies are expected to start recruitment in mid-2026, enrolling patients with advanced pancreatic cancer across leading cancer centers in New South Wales.The company will supply the investigational anti-fibrotic LOX inhibitor in addition to scientific and clinical expertise for the study, per the filing.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SNT.AU","BK7096","XKO.AU","XAO.AU","XJO.AU"],"gpt_icon":0},{"id":"2601451339","title":"Syntara Ltd-Company Secretary Appointment/Resignation","url":"https://stock-news.laohu8.com/highlight/detail?id=2601451339","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601451339?lang=en_us&edition=fundamental","pubTime":"2026-01-08 11:03","pubTimestamp":1767841419,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nTUE59WMJK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","SNT.AU"],"gpt_icon":0},{"id":"2601387057","title":"Syntara Enrolls Final Patient in Drug Candidate Study for Treatment of REM Sleep Behaviour Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2601387057","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601387057?lang=en_us&edition=fundamental","pubTime":"2026-01-08 08:14","pubTimestamp":1767831259,"startTime":"0","endTime":"0","summary":"Syntara  enrolled its final patient in the Phase 2 clinical trial of its neuro-targeted anti-inflammatory therapy, SNT-4728, for the treatment of REM Sleep Behavior Disorder, according to a Thursday filing with the Australian bourse.The study evaluates the ability of SNT-4728 to reduce inflammation in brain regions linked to the progression of various neurodegenerative disorders, the filing said.The company expects top-line results from the study in the second quarter, the filing added.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["REM","BK7096","SNT.AU"],"gpt_icon":0},{"id":"2587616759","title":"Is Syntara (ASX:SNT) In A Good Position To Deliver On Growth Plans?","url":"https://stock-news.laohu8.com/highlight/detail?id=2587616759","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587616759?lang=en_us&edition=fundamental","pubTime":"2025-11-29 06:54","pubTimestamp":1764370467,"startTime":"0","endTime":"0","summary":"Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-snt/syntara-shares/news/is-syntara-asxsnt-in-a-good-position-to-deliver-on-growth-pl-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-snt/syntara-shares/news/is-syntara-asxsnt-in-a-good-position-to-deliver-on-growth-pl-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SNT.AU","BK7096","BK4157","SNT"],"gpt_icon":0},{"id":"2584979086","title":"Syntara Ltd-Chair's Address to Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2584979086","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584979086?lang=en_us&edition=fundamental","pubTime":"2025-11-20 06:25","pubTimestamp":1763591103,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nTUE9L67R4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","SNT.AU"],"gpt_icon":0},{"id":"2571213318","title":"Syntara's Final Phase 2 Results Underscore Safety, Tolerability, Says Euroz Hartleys, Shares Jump 19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2571213318","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571213318?lang=en_us&edition=fundamental","pubTime":"2025-09-30 14:08","pubTimestamp":1759212538,"startTime":"0","endTime":"0","summary":"Syntara's  final phase 2 results for its myelofibrosis drug candidate SNT-5505 have shown that the drug was safe and well-tolerated, according to a Tuesday note from Euroz Hartleys.According to the note, the drug candidate has shown symptom improvement as well as spleen volume reduction in the trial.The research firm also noted that the company has appointed several global experts to a new strategic and clinical advisory board, including Adam Craig, former chief executive of BioPharma.Euroz Hartleys has maintained its speculative buy rating on Syntara with a price target of AU$0.22.The company's shares rose almost 19% in recent Tuesday trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","SNT.AU"],"gpt_icon":0},{"id":"2558611700","title":"FDA Feedback Pushes Back Syntara Myelofibrosis Drug Candidate Commercial Launch by Around Two Years, Euroz Hartleys Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2558611700","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558611700?lang=en_us&edition=fundamental","pubTime":"2025-08-12 15:19","pubTimestamp":1754983154,"startTime":"0","endTime":"0","summary":"The US Food and Drug Administration's  feedback to Syntara  pushes back the assumed commercial launch for its amsulostat drug candidate in the treatment of myelofibrosis by around two years., Euroz Hartleys said in a note on Tuesday.Syntara received formal feedback from the FDA on the clinical pathway for amsulostat. The regulator took a more conservative stance, recommending a standalone, placebo-controlled phase 2b trial, rather than moving directly into the originally planned phase 2c/3 study.The feedback does not alter Amsulostat's clinical profile, the strength of Syntara's broader pipeline, or its ability to secure a partner, the investment firm noted.This new timeline reduces near-term spending requirements and extends its cash runway into 2027.The investment firm maintained its rating at speculative buy and lowered its price target to AU$0.22 per share from AU$0.33 per share.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SNT.AU","BK7096"],"gpt_icon":0},{"id":"2558803756","title":"Syntara Says US FDA Provides Guidance for Phase 2 Trial for Myelofibrosis Drug Candidate; Shares Plunge 47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2558803756","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558803756?lang=en_us&edition=fundamental","pubTime":"2025-08-11 09:26","pubTimestamp":1754875609,"startTime":"0","endTime":"0","summary":"Syntara  said the US Food and Drug Administration  provided guidance that a phase 2 trial with a control arm be undertaken for its amsulostat drug candidate for the potential treatment of myelofibrosis to acquire additional safety and efficacy data, focusing on improvements in symptoms and spleen volume reductions, according to a Monday Australian bourse filing.This data will be used to optimize the design and efficiency of a subsequent pivotal phase 3 trial, the filing said.The regulator reviewed data from the ongoing open-label trial of amsulostat in combination with ruxolitinib, as well as a proposal for a pivotal registrational study.The firm's shares plunged 47% in early trading on Monday.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SNT.AU","BK7096"],"gpt_icon":0},{"id":"2556852956","title":"Syntara Ltd-Quarterly Update Webinar Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2556852956","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556852956?lang=en_us&edition=fundamental","pubTime":"2025-08-01 08:33","pubTimestamp":1754008428,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250801:nTUE9KPYNZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SNT.AU","BK7096"],"gpt_icon":0},{"id":"2556851779","title":"Syntara Ltd-Appendix 4C Quarterly Webinar","url":"https://stock-news.laohu8.com/highlight/detail?id=2556851779","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556851779?lang=en_us&edition=fundamental","pubTime":"2025-08-01 07:01","pubTimestamp":1754002918,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250731:nTUE9BZHZP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SNT.AU","BK7096"],"gpt_icon":0},{"id":"2555067388","title":"Syntara Ltd-Quarterly Shareholder Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2555067388","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555067388?lang=en_us&edition=fundamental","pubTime":"2025-07-30 07:47","pubTimestamp":1753832828,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250729:nTUEK8SYW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","SNT.AU"],"gpt_icon":0},{"id":"2555084502","title":"Syntara Doses First Patient in Hypertrophic Scar Treatment Drug Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2555084502","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555084502?lang=en_us&edition=fundamental","pubTime":"2025-07-29 13:16","pubTimestamp":1753766208,"startTime":"0","endTime":"0","summary":"Syntara  said the first patient was dosed with topical anti-fibrotic drug SNT-9465 as part of its phase 1a/b  clinical trial for the treatment of hypertrophic scars, according to a Tuesday filing with the Australian bourse.The trial's main objective is to determine the optimal dose of the drug, the filing said.The results of the trial are expected in the first half of 2026, the filing added.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","SNT.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":12,"code":"91000000","status":"200"}]}}